Laura Miller

Precision Veterinary Countermeasures platform to decode host-pathogen interplay across multiple and diverse high-consequence pathogens, companion animal diseases, and translational models. By integrating classical immunology with multi-omics and machine learning, my laboratory translates fundamental host transcriptional insights directly into developing field-ready biosecurity tools, AI-driven diagnostics, and next-generation interventions.

·      Extramurally Funded Countermeasure & Diagnostic Platforms: Leading competitive federal initiatives as PI and Co-PI to develop edible oral vaccine delivery systems for avian pathogens, build AI-enhanced point-of-care surveillance applications for field containment, and resolve host-pathogen transcriptomic responses using primary organoid models.

·      Translational Cooperative Research: Directing investigator-initiated federal cooperative agreements across viral pathogens to evaluate vector-borne biosecurity interfaces, measure immunogenicity of plant-expressed virus-like particle candidates, and optimize transdermal microneedle delivery platforms in large-animal models.

·      Intramural Commercialization & Seed Initiatives: Maximized competitive internal seed mechanisms to launch original translational pipelines, including an ISA-based platform producing broadly protective porcine vaccines, patented AI-assisted diagnostic software, and interdisciplinary computational models.

·      Spatial Transcriptomics & Biomarker Discovery: As Lead Scientist, I designed original spatial molecular imaging panels to resolve uncharacterized immune microenvironments during acute viral infection across non-traditional target species. Supported by institutional infrastructure resources, this program has established active fee-for-service and collaborative research networks with human and veterinary medical centers, supporting pending national health proposals and cancer research initiatives.

·      Commercialization & Technology Transfer: Translational impact is a hallmark of my scholarship. To maximize real-world application, my program actively translates complex immunological signatures into commercialized reagents, point-of-care tools, and real-time field surveillance. My discoveries in swine viral genomics, pathobiology, and cell lines have yielded six active corporate license agreements, modified live vaccine candidates, and patented point-of-care diagnostic tools scheduled for university-wide technology showcases.

·      National & International Peer Recognition: I have delivered invited keynote addresses at premier international venues, including the Conference of Research Workers in Animal Diseases (CRWAD), the American Association of Immunologists (AAI), the International Plant and Animal Genome Conference (PAG), and the International PRRS Symposium (IPRRSS). In 2026, I was appointed to the World Organisation for Animal Health (WOAH) PROEVA ad hoc expert committee establishing Target Product Profiles for next-generation swine vaccines, and selected as a Gordonstoun Fellow in recognition of international scientific service.